1Q sales performance is a joke!!! Go out there and SELL!! Y'all call yourselves a sales force?
hcv
- Thread starter anonymous
- Start date
-
- Tags
- None
I saw the numbers as well with the earnings release. Something needs to be done and forget 2nd generation if this management team is still in place. Sorry but results drive sustained employment!!
WTF--- VPak US sales down -55% compared to 3q15
3q15@ $242M
1q16@ $125M
Vpak sales in US are even down to a year ago, 1Q15 by 9.5%. That's pathetic. It was just starting out a year ago!!
We beat the street and Ricky's celebrating all weekend. Good job Rick Keep it up. Keep acquiring more backup for 2022 when Humira sales will trickle down. We love Abbvie and no layoffs coming here.
well stated !!!! the former cardio reps are real sorry they couldn't stay like us !
Even Bristol-Myers Squibb beat us in 1q16
1q16 HCV Global Revenues ($B)
Gilead - 4.294
Bristol-Myers Squibb - 0.427
Merck - tbd 5/5/16
Abbvie - 0.414
Johnson& Johnson - 0.032
Who cares about HCV. That's where the folks that Ricky suckered and played out work.
Humira Legacy Rep
Humira Legacy Rep
Even Bristol-Myers Squibb beat us in 1q16
1q16 HCV Global Revenues ($B)
Gilead - 4.294
Bristol-Myers Squibb - 0.427
Merck - tbd 5/5/16
Abbvie - 0.414
Johnson& Johnson - 0.032
Tom and Emil said you deserved to go. Good Riddance !
I hate to say it but this has been the WORST LAUNCH in pharma history!! Ricky went forward with this disaster and the Board must let him go!!!
It's clear that Louie was brilliant after all. 51...as in $51 million in sales for Q3.
Ricky couldn't launch a turd into a toilet.....BWAAA HAAA PLAY ON
Ouch...good think Haas got that promotion...well deserved.Even Bristol-Myers Squibb beat us in 1q16
1q16 HCV Global Revenues ($B)
Gilead - 4.294
Bristol-Myers Squibb - 0.427
Merck - tbd 5/5/16
Abbvie - 0.414
Johnson& Johnson - 0.032
Gilead stock is tanking ....Rampant layoffs in ONC and HV at Gilead. Foster City is in a panic mode. CEO Milligan is a corporate thief stealing from Patients, America, Veterans, and Taxpayers. .....The biggest scumbag is Dr. Raymond Schinazi, a VA doctor since 1983, he founded Pharmasset and led the scientific team that discovered sofosbuvir while working at VA on the Taxpayers dime....Sold it all for $400 Million .....Who really owns the hepatitis C cure? Taxpayers or the VA employee who invented it while a full-time VA employee? Don't ever talk about Ricky,at least our hep c is priced reasonably. We had no part in this scam.
Big talk considering we have more lawyers than scientists on payroll...hmmm...I wonder why??
You sound like a displaced RD Lib from West Coast. White was smart spinning Abbvie
He saved all the wasted RD money. Abbott hadScientists that couldn't discover a turd in the hopper. Most blockbusters came from company's Abbott/Abbvie acquired not from in house RD. Now y'all can wipe your ass with MBA and PHDs.They mean nothing when your not employed and bumming all day !
He saved all the wasted RD money. Abbott hadScientists that couldn't discover a turd in the hopper. Most blockbusters came from company's Abbott/Abbvie acquired not from in house RD. Now y'all can wipe your ass with MBA and PHDs.They mean nothing when your not employed and bumming all day !
1q16 HCV Global Status
- Gilead maintained q/q same global market share
- Bristol-Myers Squibb gained 0.5%
- Abbvie VPak lost -1.4%
- New player Merck quickly acquired 1.0%
Very disappointing results! Abbvie Retirees
This is a lost cause in the U.S, Absolutely terrible sales and there is no light in sight.
They need to devote at most 1 rep per multi state territory to meet with few writers and provide samps.
Metabolics is dead and HCV is GOING down the drain (no longer just circling it)
Looks Like Abbvie And Jeff Haas is kicking Gileads Ass. Go HAAS Go
Earlier Thursday, AbbVie reported a 79% increase in first-quarter Viekira Pak sales, to $414 million . AbbVie Inc. markets Viekira Pak, a competing and similarly costly treatment it launched in late 2014. Gilead has managed to protect much of its market share, but analysts have cautioned that pressure is heating up. “People are worried about the hepatitis C market,
Gilead Science Inc.'s earnings tumbled more than 17 percent in the first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales.Gilead has become an unwilling poster-child for high drug prices, due to the staggering list prices for the hepatitis drugs: about $94,000 for Harvoni and $84,000 for Sovaldi. Insurers in the U.S. have demanded steep discounts — as much as 45 percent — to cover the two drugs, but their prices are straining budgets from the Veterans Affairs system to state Medicaid programs.
Earlier Thursday, AbbVie reported a 79% increase in first-quarter Viekira Pak sales, to $414 million . AbbVie Inc. markets Viekira Pak, a competing and similarly costly treatment it launched in late 2014. Gilead has managed to protect much of its market share, but analysts have cautioned that pressure is heating up. “People are worried about the hepatitis C market,
Gilead Science Inc.'s earnings tumbled more than 17 percent in the first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales.Gilead has become an unwilling poster-child for high drug prices, due to the staggering list prices for the hepatitis drugs: about $94,000 for Harvoni and $84,000 for Sovaldi. Insurers in the U.S. have demanded steep discounts — as much as 45 percent — to cover the two drugs, but their prices are straining budgets from the Veterans Affairs system to state Medicaid programs.